Literature DB >> 16142341

A role for PI3K-Akt signaling in pulmonary metastatic nodule formation of the osteosarcoma cell line, LM8.

Yasushi Fukaya1, Naoki Ishiguro, Takeshi Senga, Yasukatsu Ichigotani, Yasuyoshi Sohara, Motomu Tsutsui, Tomone Shioura, Takashi Iwamoto, Michinari Hamaguchi.   

Abstract

To search for the intracellular signaling pathway critical for the pulmonary metastasis of osteosarcoma, we examined two osteosarcoma cell lines with different metastatic capability, Dunn and LM8. While parental Dunn is poorly metastatic to lung, LM8, derived from Dunn by in vivo selection through pulmonary metastasis, displays clear capability of pulmonary metastasis. We found that LM8 had higher levels of Akt phosphorylation and Ezrin expression than Dunn. In contrast, no clear difference was observed between Dunn and LM8 in other signaling mediators, including MAPK, SAPK and Stat3. In contrast to Dunn, LM8 secreted higher levels of matrix metalloproteinase-2 and -9, showed higher levels of invasiveness and cell motility, and displayed strong pulmonary metastasis. Inhibition of PI3K-Akt signaling in LM8 by a PI3K inhibitor, LY294002, or by a dominant negative form of Akt, resulted in suppression of MMP secretion, in vitro invasiveness, cell locomotion and in vivo pulmonary metastasis. In contrast, expression of an active form of Akt in Dunn substantially activated its MMP secretion, in vitro invasiveness, cell locomotion and in vivo pulmonary metastasis. Taken together, our results demonstrate, for the first time, an important role of Akt signaling in pulmonary metastasis of osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16142341

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  16 in total

Review 1.  Osteosarcoma metastasis: prospective role of ezrin.

Authors:  Yuanjin Zhang; Ling Zhang; Guofu Zhang; Songbai Li; Jun Duan; Jie Cheng; Guozhen Ding; Chibing Zhou; Jie Zhang; Pengcheng Luo; Dongbing Cai; Lianghong Kuang; Yichun Zhou; Liqun Tong; Xiangdong Yu; Lifang Zhang; Lijun Xu; Li Yu; Xiaomei Shi; Aihong Ke
Journal:  Tumour Biol       Date:  2014-03-09

2.  Biomarkers in Osteosarcoma.

Authors:  Colin Kong; Marc F Hansen
Journal:  Expert Opin Med Diagn       Date:  2009-01-01

3.  Stable knockdown of S100A4 suppresses cell migration and metastasis of osteosarcoma.

Authors:  Masahiko Fujiwara; Takeshi G Kashima; Akiko Kunita; Isao Kii; Daisuke Komura; Agamemnon E Grigoriadis; Akira Kudo; Hiroyuki Aburatani; Masashi Fukayama
Journal:  Tumour Biol       Date:  2011-03-01

4.  Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.

Authors:  Yun-Rong Zhu; Han Min; Jian-Feng Fang; Feng Zhou; Xiong-Wei Deng; Yun-Qing Zhang
Journal:  Cancer Biol Ther       Date:  2015-04-14       Impact factor: 4.742

5.  Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression.

Authors:  Amer K Karam; Chintda Santiskulvong; Mirela Fekete; Sara Zabih; Carol Eng; Oliver Dorigo
Journal:  Cytoskeleton (Hoboken)       Date:  2010-08

6.  Apoptosis resistance and PKC signaling: distinguishing features of high and low metastatic cells.

Authors:  Sung-Hyeok Hong; Ling Ren; Arnulfo Mendoza; Ananth Eleswarapu; Chand Khanna
Journal:  Neoplasia       Date:  2012-03       Impact factor: 5.715

7.  Effect of troglitazone on tumor growth and pulmonary metastasis development of the mouse osteosarcoma cell line LM8.

Authors:  Junichi Aizawa; Kenshi Sakayama; Setsuya Kamei; Teruki Kidani; Haruyasu Yamamoto; Yoshiaki Norimatsu; Hiroshi Masuno
Journal:  BMC Cancer       Date:  2010-02-22       Impact factor: 4.430

8.  Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors.

Authors:  Serena S Freeman; Steven W Allen; Ramapriya Ganti; Jianrong Wu; Jing Ma; Xiaoping Su; Geoff Neale; Jeffrey S Dome; Najat C Daw; Joseph D Khoury
Journal:  Cancer       Date:  2008-09-15       Impact factor: 6.860

9.  Inhibition of hyaluronan retention by 4-methylumbelliferone suppresses osteosarcoma cells in vitro and lung metastasis in vivo.

Authors:  E Arai; Y Nishida; J Wasa; H Urakawa; L Zhuo; K Kimata; E Kozawa; N Futamura; N Ishiguro
Journal:  Br J Cancer       Date:  2011-11-01       Impact factor: 7.640

10.  Osteosarcoma models: from cell lines to zebrafish.

Authors:  Alexander B Mohseny; Pancras C W Hogendoorn; Anne-Marie Cleton-Jansen
Journal:  Sarcoma       Date:  2012-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.